The overall aim of this project is to analyze and summarize existing dispensing models and effective practices in the care of patients with multiple myeloma.
As the number of oral anticancer medications continues to increase, new challenges for education, delivery, and adherence are also increasing. The changing landscape of how these therapies are dispensed in the community introduces additional complexities and potential obstacles to both access and treatment adherence.
Within existing dispensing models, cancer programs and practices must assess how to most effectively achieve timely, effective delivery of therapies to their patients.
ACCC is conducting this education program to understand how the current dispensing landscape is affecting delivery of oral therapies for patients with multiple myeloma. To better understand the impact on providers and patients, ACCC is conducting a series of focus group discussions that will explore:
This research will help to identify case examples of efficient, effective dispensing models, which will inform development of a toolkit of resources and furnish topics for a live webinar series that will review existing dispensing models, discuss obstacles and effective practices, and provide opportunity for Q&A.
The Association of Community Cancer Centers (ACCC) Oncology Pharmacy Education Network (OPEN) has conducted a Multiple Myeloma Dispensing Models education program to understand how the current dispensing landscape is affecting delivery of oral therapies for patients with Multiple Myeloma.
To better understand the impact on providers and patients, this publication features real-world case studies from three cancer programs that analyze and summarize their existing dispensing models and practices in caring for patients with multiple myeloma. The publication addresses the dispensing of oral oncolytics in relation to:
Designed with all members of the multidisciplinary care team in mind, this publication offers how-to strategies to effectively achieve the safe, timely delivery of oral therapies to this patient population.
COVID-19 has impacted how providers are dispensing multiple myeloma medications and providing care to patients during the pandemic. Learn how to identify those effects to help mitigate them and implement strategies to improve telehealth medicine during the pandemic.
Learn how to better identify and utilize financial resources that are available for patients with multiple myeloma, and implement strategies to improve insurance verification procedures.
Effective communication with patients is key to providing optimal care to patients. Learn the most effective strategies for successful conversation with patients undergoing treatment for multiple myeloma and discover valuable resources that can help.
Expert faculty will Identify new emerging therapies in the care for multiple myeloma patients and provide examples of how to operationalize care of this patient population.
Causes, risk factors, and prevention vary among cancer types, and multiple myeloma presents its own unique risk factors, such as age, gender, race, and family history, among others. Learn about the various precursor conditions for multiple myeloma and how to determine the risk of developing the disease.
Learn how to identify key disparities in clinical trial access for patients with multiple myeloma and explore strategies that can help improve access for underserved communities. (October 21, 2020)